Kiora Pharmaceuticals (FRA:7EY) Insider Ownership: 0.00 % (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7EY Kiora Pharmaceuticals Inc FRA:7EY
34 GF Score
Price €0.42
! 4 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Insider Ownership?

Kiora Pharmaceuticals FRA:7EY 34 Insider Ownership is 0.00 % as of Sep. 09, 2026. GuruFocus rates FRA:7EY with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kiora Pharmaceuticals's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kiora Pharmaceuticals's Institutional Ownership is 1.22%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kiora Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 96.95%.

Kiora Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Insider Ownership Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiora Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7EY
34GF Score
Kiora Pharmaceuticals Inc FRA:7EY
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Kiora Pharmaceuticals (FRA:7EY) has a Insider Ownership of 0.00 % as of Sep. 09, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' Insider Ownership too high?
Kiora Pharmaceuticals' current Insider Ownership is 0.00 %. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Insider Ownership compare to SNTI and PDSB?
Kiora Pharmaceuticals' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (FRA:7EY) has a current Insider Ownership of 0.00 %. The current Insider Ownership is 0.00 %. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Kiora Pharmaceuticals (FRA:7EY), the current Insider Ownership is 0.00 % as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Other Exchanges KPRX:USA
Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for FRA:7EY

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price